Dr. Lars Peterson, Co-founder of Artelon
A medical need is identified, to create a synthetic material to support ligament reconstruction, specifically the ACL reconstruction where previous products failed time and time again. Looking to find a solution, Lars Peterson, MD. and Per Flodin (Professor of Polymer Technology), Co-founders of Artimplant started on efforts to develop a new biomaterial. During subsequent years, development of material, product, and production takes place and the technology is verified through preclinical trials. A conversation over coffee a decade earlier between the two company Co-Founders turns out to have benefits for tens-of-thousands of patients worldwide in the years to come.
The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.
The first multicenter trial in ACL reconstruction is concluded with excellent outcomes.
The second multicenter ACL reconstruction trial begins. Artimplant’s Artelon patent is approved in the USA and Europe.
The first product, the Artelon Augmentation Device ACL is granted CE-certification and can now be marketed in Europe.
Artimplant’s Artelon CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing
in Europe. Artelon Surgical Suture is given clearance by the FDA for sales on the American market.
Artelon CMC Spacer receives clearance for marketing from the FDA for sales on the US market. Licensing agreements signed with Small Bone Innovations. A licensing agreement is signed with Biomet Inc. for the production of SportMesh™.
Artelon implant for reinforcing rotator cuffs is cleared for marketing in Europe.
The Company receives clearance for marketing by the FDA for the sale of the SportMesh™ rotator cuff implant in the USA.
The FDA grants clearance to market Artelon Tissue Reinforcement for soft tissue reinforcement in several new indications in the USA. Two new Spacer products for osteoarthritis in the hand are granted clearance by the FDA for marketing in the USA.
All patients enrolled for the American post-market study of Artelon® Tissue Reinforcement for the treatment of patients with tears in the rotator cuff tendons.
The American post-market study on Artelon® Tissue Reinforcement for the treatment of the rotator cuff in the shoulder is concluded.
On April 1, the agreement with Biomet and Small Bone Innovations was terminated to allow for additional company oversight.
The Artelon products were acquired, out of bankruptcy, by International Life Sciences, LLC a United States based company. In an effort to honor the history and efforts of the Swedish creators, the company made a decision to continue using the name Artelon not only for the products, but also as the name the company does business under. The international headquarters of Artelon was moved to Nashville, TN, but continues to provide Artelon Tissue Reinforcement to the world. In an effort to focus sales on the most significant opportunity, the company made a strategic decision to no longer sell any of the spacer products and focus on soft tissue reinforcement in the orthopedic and podiatric market.
Manufacturing efforts in the USA are undertaken, with full manufacturing capabilities to be available by mid 2016. New and aggressive initiatives to validate the efficacy of Artelon Material are underway with extensive research, laboratory testing and case studies being completed by various surgeons and research institutions.